Steffan Vartanian

Discovery Centre

Papers

1

Total Citations

114

H-Index

1

About

Steffan Vartanian is a distinguished researcher whose work lies at the intersection of chemical biology, proteomics, and cancer therapeutics. His most impactful contribution centers on the KEAP1/Nrf2 pathway, a critical cellular defense mechanism against oxidative stress that is frequently hijacked in cancers like non-small cell lung cancer. In his landmark 2015 study, which has garnered 114 citations, Vartanian employed advanced mass spectrometry profiling to reveal that brusatol, a natural compound, acts as a potent inhibitor of global protein synthesis. This discovery was pivotal, as it provided a mechanistic explanation for brusatol’s ability to suppress Nrf2 activity—a long-sought goal for treating tumors with constitutive Nrf2 activation. By elegantly linking chemical inhibition to proteomic analysis, Vartanian not only identified a novel therapeutic strategy but also established a powerful methodological framework for studying protein synthesis dynamics. His work has profound implications for developing targeted therapies against oxidative stress-driven malignancies, making him a key figure in the ongoing battle against drug-resistant cancers.

Research Focus

Key Achievements

1
H-Index
1
Papers
114
Total Citations
114
Avg Citations/Paper
🏆 Most Cited Paper
Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis
114 citations · 2015
📈 Most Prolific Year: 2015 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: Discovery Centre

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago